X4 Pharmaceuticals
XFOR
89 hedge funds and large institutions have $463M invested in X4 Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 27 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
19% more capital invested
Capital invested by funds: $388M → $463M (+$75M)
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
6% more funds holding
Funds holding: 84 → 89 (+5)
1.84% more ownership
Funds ownership: 103.28% → 105.13% (+1.8%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.8M |
| 2 |
VA
VR Adviser
New York
|
+$6.58M |
| 3 |
PA
Perceptive Advisors
New York
|
+$4.91M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.75M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$8.26M |
| 2 |
Millennium Management
New York
|
-$5M |
| 3 |
SC
Stempoint Capital
New York
|
-$3.51M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.46M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.89M |
XFOR Hedge Fund Activity: Q2 2026 in Review
89 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2026, worth a combined $463M — up 19% from $388M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new XFOR positions and 27 closed out — a net gain of 5 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $17.8M. The largest seller was Empery Asset Management, cutting an estimated $8.26M.
- 89 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2026, up from 84 in Q1 2026.
- Funds reported $463M of X4 Pharmaceuticals stock for Q2 2026, up 19% quarter-over-quarter.
- 32 funds opened new X4 Pharmaceuticals positions in Q2 2026 and 27 closed out, a net change of +5 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $17.8M added.
- The largest X4 Pharmaceuticals seller in Q2 2026 was Empery Asset Management, an estimated $8.26M sold.
Based on aggregated 13F filings for Q2 2026.